SGLT2 i physiologically elevates blood ketone bodies such as β-hydroxybutyrate, which can modulate NLRP3 inflammasome-IL-1β signaling, and a key pathologic pathway in AD. Here, SLC5A2 is linked to Alzheimer disease.